A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin

The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)

Inclusion Criteria:

• Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant.
• Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires.
• Age ≥ 18 years at the time of consent.
• ECOG Performance Status of ≤ 3 within 28 days prior to consent.
• Histological or cytologically confirmed urothelial carcinoma.
• Patients must be planned to start systemic therapy with enfortumab vedotin
• At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

• Inability of the subject to understand and comply with study procedures.
• Having previously received enfortumab vedotin
• Students/employees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).